NLRX1 and inflammatory bowel disease: As a proof of principle, Leber et al., 2019a developed a small molecule, NX-13, that showed anti-inflammatory effects by activating NLRX1 of a small molecule in an in vivo model of inflammatory bowel disease (Leber et al., 2019a; Leber et al., 2019b).